{
    "url_original": "https://www.wsj.com/articles/abbotts-rapid-covid-19-tests-boost-quarterly-sales-growth-11643208574?mod=business_lead_pos2",
    "url": "abbotts-rapid-covid-19-tests-boost-quarterly-sales-growth-11643208574",
    "title": "Abbott’s Rapid Covid-19 Tests Boost Quarterly Sales Growth",
    "sub_head": "Rapid-test brands sold $2.1 billion of diagnostics in the last quarter of 2021, but company forecasts lower demand this year",
    "category_1": "Business",
    "category_2": "Earnings",
    "time": "2022-01-26 12:11:00",
    "body": "Abbott Laboratories ,  one of America’s largest producers of rapid tests for Covid-19, said that testing-related sales were $2.3 billion globally in the last three months of 2021 but forecast that demand for the tests will slow this year.<br />Rapid-test sales from Abbott’s BinaxNow, Panbio and ID NOW brands grew to $2.1 billion, from $1.9 billion in 2020’s fourth quarter, as the comparable stretch of 2021 included a surge in world-wide cases from the Omicron variant."
}